Neuronal Cell-State Profiles in Epilepsy: Mechanisms, Clinical Implications, and Emerging Therapeutic Horizons

Abstract

Epilepsy, a chronic neurological disorder characterized by recurrent unprovoked seizures, exhibits profound heterogeneity at the cellular and molecular levels within the central nervous system. Recent advances in single-cell transcriptomics and neuroimaging have facilitated the delineation of neuronal cell-state profiles, uncovering distinct pathophysiological signatures underlying epileptogenesis and chronic epilepsy. This review synthesizes current evidence regarding neuronal cell-state dynamics in epilepsy, emphasizing the mechanistic underpinnings, clinical manifestations, diagnostic strategies, and therapeutic implications. Emphasis is placed on the integration of cell-state profiling with clinical practice, potential for targeted interventions, and future directions in personalized epilepsy management.

Introduction

Epilepsy affects approximately 50 million individuals worldwide, representing a significant public health concern due to its chronicity, neurocognitive comorbidities, and impact on quality of life. The pathogenesis of epilepsy is multifactorial, involving genetic, structural, metabolic, immune, and infectious etiologies. Central to disease progression is the maladaptive alteration of neuronal circuits and cell states, culminating in hyperexcitability and hypersynchrony. Recent technological advancements—particularly in single-cell RNA sequencing and spatial transcriptomics—have enabled unprecedented resolution in mapping neuronal cell-state heterogeneity in both experimental models and human epileptic tissue. Understanding these profiles is essential for elucidating the mechanisms of seizure initiation, propagation, and chronicity, as well as for informing the development of precision therapeutics.

Epidemiology / Disease Burden

Epilepsy accounts for a substantial global disease burden, with an estimated incidence ranging from 30 to 50 per 100,000 person-years and a lifetime prevalence of 4–10 per 1,000 individuals. The disorder is responsible for significant morbidity, including neurocognitive impairment, psychiatric comorbidities, and increased risk of premature mortality. Treatment-resistant epilepsy (TRE), defined as failure to achieve seizure control with adequate trials of two tolerated and appropriately chosen antiepileptic drugs (AEDs), affects nearly one-third of patients. In this population, the underlying neuronal cell-state abnormalities are often more pronounced, underscoring the importance of advanced molecular profiling for clinical stratification and management.

Pathophysiology

Epileptogenesis is characterized by complex alterations in neuronal cell states, driven by genetic mutations, synaptic remodeling, gliosis, and neuroinflammatory processes. Single-cell transcriptomic analyses have identified distinct populations of hyperexcitable pyramidal neurons, interneuron dysfunction, and aberrant glial activation in epileptic foci. Notably, changes in gene expression related to ion channels (such as SCN1A, KCNQ2), neurotransmitter receptors (GABA_A, NMDA), and synaptic proteins (synapsin, neuroligin) contribute to the shift towards a pro-epileptogenic state. Microenvironmental factors, including cytokines, chemokines, and reactive oxygen species, further modulate neuronal plasticity and network excitability. The interplay between neuronal and non-neuronal cells in defining cell-state profiles is increasingly recognized as a critical determinant of seizure susceptibility and chronic epilepsy.

Risk Factors

Risk factors for epilepsy and its progression include genetic predisposition, traumatic brain injury, perinatal insults, CNS infections, and autoimmune encephalitides. At the cellular level, mutations affecting ion channel function or synaptic architecture predispose to aberrant neuronal firing and network synchronization. Environmental and lifestyle factors, such as sleep deprivation, stress, and substance use, can precipitate alterations in neuronal cell states, lowering the seizure threshold. Age-related changes in neuronal plasticity and glial reactivity also contribute to differential risk across the lifespan, with a notable predilection for early childhood and late adulthood.

Clinical Features

Epilepsy presents with a spectrum of clinical manifestations, ranging from focal aware seizures to generalized convulsive episodes. The clinical phenotype is influenced by the underlying neuronal cell-state profile, with certain molecular signatures correlating with specific seizure types, frequency, and response to therapy. For example, interneuron deficits are often linked to temporal lobe epilepsy and pharmacoresistance, while hyperexcitable glutamatergic networks are implicated in generalized epilepsies. Cognitive impairment, mood disorders, and behavioral disturbances are common comorbidities, reflecting widespread disruption of neuronal and glial cell states beyond epileptic foci.

Diagnosis

Diagnosis of epilepsy relies on a combination of clinical evaluation, electroencephalography (EEG), neuroimaging, and increasingly, molecular profiling. High-resolution MRI and functional imaging can localize epileptogenic zones and reveal structural correlates of altered cell states, such as hippocampal sclerosis or cortical dysplasia. Emerging diagnostic modalities—such as single-cell transcriptomics of resected tissue or peripheral biomarkers of neuronal injury—offer promise in refining etiological classification and predicting treatment response. Advanced EEG techniques, including source localization and network analysis, further elucidate the impact of neuronal cell-state dynamics on seizure generation and propagation.

Treatment & Management

Management of epilepsy encompasses pharmacological, surgical, and neurostimulation approaches, tailored to the individual\'s seizure type, comorbidities, and underlying pathology. Antiepileptic drugs remain the mainstay, targeting ion channels and neurotransmitter systems to restore physiological neuronal firing. In refractory cases, surgical resection of epileptogenic tissue—guided by cell-state profiling and intraoperative monitoring—offers the potential for seizure freedom. Neurostimulation modalities, such as vagus nerve stimulation (VNS) and responsive neurostimulation (RNS), modulate neuronal network activity and have demonstrated efficacy in select populations. Personalized medicine approaches, informed by neuronal cell-state profiles, are emerging as a promising avenue for optimizing treatment selection and minimizing adverse effects.

Recent Advances / Emerging Therapies

Recent years have witnessed significant breakthroughs in the application of single-cell technologies, CRISPR-based gene editing, and cell-based therapies in epilepsy. Single-cell sequencing has enabled the identification of novel molecular targets and druggable pathways specific to aberrant neuronal cell states. Experimental therapies—such as interneuron transplantation, modulation of neuroinflammatory pathways, and targeted delivery of gene therapies—are under investigation in preclinical and early-phase clinical studies. Pharmacogenomic profiling and machine learning algorithms are being integrated into clinical practice to predict drug response and tailor interventions based on individual neuronal cell-state signatures.

Guideline Recommendations

Professional guidelines from organizations such as the International League Against Epilepsy (ILAE) and American Academy of Neurology (AAN) emphasize the importance of comprehensive diagnostic evaluation and individualized treatment planning. Although routine use of neuronal cell-state profiling is not yet standard of care, guidelines endorse the integration of advanced neuroimaging, genetic testing, and, where available, molecular diagnostics to inform clinical decision-making. Multidisciplinary care—incorporating neurology, neurosurgery, neuropsychology, and molecular pathology—is advocated for patients with refractory or complex epilepsy.

Conclusion

Neuronal cell-state profiling represents a transformative advance in the understanding and management of epilepsy, bridging the gap between molecular mechanisms and clinical practice. Ongoing research is poised to translate these insights into precision diagnostics and targeted therapies, with the ultimate goal of improving outcomes for individuals living with epilepsy. Continued investment in single-cell technologies, biomarker discovery, and translational research is essential to realize the full potential of personalized epilepsy care.